An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Cue Health Inc. (HLTH) is set to release its first quarter 2024 financial results on May 13, 2024, without hosting a conference call.
Cue Health Inc. (HLTH) pubblicherà i risultati finanziari del primo trimestre del 2024 il 13 maggio 2024, senza organizzare una conferenza telefonica.
Cue Health Inc. (HLTH) publicará los resultados financieros del primer trimestre de 2024 el 13 de mayo de 2024, sin realizar una conferencia telefónica.
Cue Health Inc.(HLTH)는 2024년 5월 13일에 2024년 1분기 재무 결과를 발표할 예정이며, 전화 회의는 개최하지 않습니다.
Cue Health Inc. (HLTH) communiquera ses résultats financiers pour le premier trimestre 2024 le 13 mai 2024, sans organiser de conférence téléphonique.
Cue Health Inc. (HLTH) wird am 13. Mai 2024 die Finanzergebnisse für das erste Quartal 2024 veröffentlichen, ohne eine Telefonkonferenz abzuhalten.
Positive
None.
Negative
None.
SAN DIEGO--(BUSINESS WIRE)--
Cue Health Inc. (“Cue”) (Nasdaq: HLTH), a healthcare technology company, announced today that it will release its first quarter 2024 financial results on Monday, May 13, 2024. The company will not be hosting a conference call.
About Cue Health
Cue Health Inc. (Nasdaq: HLTH) is a healthcare technology company that uses diagnostic-enabled care to empower people to live their healthiest lives. Cue’s platform offers individuals and healthcare providers convenient and personalized access to lab-quality diagnostic tests at home and at the point-of-care, as well as on-demand telehealth consultations and treatment options for a wide range of health and wellness needs. Cue’s customers include federal and state public sector agencies and the private sector, which includes healthcare providers, enterprises, and individual consumers. Cue received De Novo authorization from the U.S. Food and Drug Administration (FDA) for its COVID-19 test, which became the first home use respiratory test to receive this FDA approval. Cue also received Emergency Use Authorization from the FDA for its molecular Mpox test at the point-of-care. Cue, founded in 2010, owns over 100 patents and is headquartered in San Diego. For more information, please visit www.cuehealth.com.
